Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Initiatives
EW logo

Edwards Lifesciences Sales Hit $6.1 Billion Driven by TAVR Growth

EW10-KFiling Date: 2/25/2026
Edwards Lifesciences Corporation
Description

What this story covers

Edwards Lifesciences achieved $6.1 billion in 2025 net sales, an 11.5% increase led by its TAVR segment. Despite profitability pressure from $325.4 million in litigation and higher taxes, the company is doubling down on structural heart innovation.

Story snapshot

CompanyEdwards Lifesciences Corporation
TickerEW
VariantStandard detailed
Duration12:51
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001099800-26-000009
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in